Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment

• Published in: Journal of ovarian research Vol. 16; no. 1; p. 9
• Main Authors: Zhao, Han, Zhang, Jiaqi, Cheng, Xiangyi, Nie, Xiaozhao, He, Bing
• Format: Journal Article
• Language: English
• Published: England BioMed Central 11.01.2023; BMC
• Subjects: Female; Humans; Hyperandrogenaemia; Hyperandrogenism; Hyperinsulinism; Insulin; Insulin Resistance; Insulin sensitization therapy; Insulin signal transduction pathway; Polycystic ovary syndrome; Polycystic Ovary Syndrome - genetics; Polycystic Ovary Syndrome - therapy; Review; Polycystic ovary syndrome; Insulin resistance; Insulin sensitization therapy; Hyperandrogenaemia; Insulin signal transduction pathway
• ISSN: 1757-2215; 1757-2215
• DOI: 10.1186/s13048-022-01091-0

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by chronic ovulation dysfunction and overabundance of androgens; it affects 6-20% of women of reproductive age. PCOS involves various pathophysiological factors, and affected women usually have significant insulin resistance (IR), which is a major cause of PCOS. IR and compensatory hyperinsulinaemia have differing pathogeneses in various tissues, and IR varies among different PCOS phenotypes. Genetic and epigenetic changes, hyperandrogenaemia, and obesity aggravate IR. Insulin sensitization drugs are a new treatment modality for PCOS. We searched PubMed, Google Scholar, Elsevier, and UpToDate databases in this review, and focused on the pathogenesis of IR in women with PCOS and the pathophysiology of IR in various tissues. In addition, the review provides a comprehensive overview of the current progress in the efficacy of insulin sensitization therapy in the management of PCOS, providing the latest evidence for the clinical treatment of women with PCOS and IR.